A recently published multicentric retrospective study in France indicated that locoregional treatment improved overall survival in breast cancer patients with synchronous metastasis, especially in patients with the molecular subtype of HR-positive/HER2-negative and HER2-positive (27). This evidence concerns the gene ERBB2 and breast carcinoma.